Home Tags Sacituzumab govitecan

Tag: Sacituzumab govitecan

Immunomedics and Everest Signs License Agreement for Sacituzumab Govitecan

In late April 2019 Immunomedics and Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, confirmed that the companies had signed an exclusive license...

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...

2017 San Antonio Breast Cancer Symposium will Highlight Several Antibody-Drug Conjugates...

This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...
ESMO 2017 - 3

Interim Phase II Results with Sacituzumab Govitecan in Pretreated Metastatic Urothelial...

Results from an interim Phase II study with sacituzumab govitecan (IMMU-132) shows that the investigational agent is active in patients with metastatic urothelial cancer...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Seattle Genetics and Immunomedics Terminate License Agreement for Sacituzumab Govitecan

Seattle Genetics and Immunomedics today confirmed that they have terminated their Exclusive Global Licensing Agreement for sacituzumab govitecan (IMMU-132), Immunomedics breakthrough therapy candidate to...

Sacituzumab Govitecan Show Promising Results in Patients with Advanced Triple-negative Breast...

A clinical trial of an antibody-drug conjugate that combines the active portion of a chemotherapy drug with an antibody targeting a molecule expressed on...

Seattle Genetics to Lead Global Development, Manufacturing and Commercialization of Sacituzumab...

The global biotechnology company Seattle Genetics earlier today confirmed development and icencing agreement with Immunomedics. Under the terms of the agreement, Seattle Genetics receives...

Antitumor Effect of Sacituzumab Govitecan in Triple-Negative Breast Cancer Can be...

Based on a pre-clinical study, treatment of patients sacituzumab govitecan, also known as  IMMU-132 (Immunomedics), in patients with metastatic triple-negative breast cancer (mTNBC) has...

New Patents Awarded for Immunomedics’ Antibody-drug Conjugates Development Program

Earlier this week Immunomedics announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent 9,492,566, the 32nd U.S. patent protecting the...

DOWNLOAD